Testing a new treatment for bronchiectasis lung disease

Plain-English translation of NCT07547436 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called to see if it can help reduce mucus buildup in the airways of people with non-cystic fibrosis bronchiectasis, a chronic lung disease. The medication will be compared to placebo (an inactive pill) to measure how well it works and whether it is safe. About 70 people aged 18 to 80 will participate in this study.

Non-cystic fibrosis bronchiectasis causes permanent damage to the airways, leading to chronic cough, excessive mucus production, and repeated respiratory infections. There is a need for new treatments to help reduce mucus buildup and improve quality of life for people living with this condition.

Do you qualify?

You likely qualify if…

you are between 18 and 80 years old
you have been diagnosed with non-cystic fibrosis bronchiectasis confirmed by chest imaging
you have a chronic productive cough and history of recurrent respiratory infections
you have had at least 2 respiratory infections in the past 12 months requiring antibiotics prescribed by a doctor
your lung function (measured as FEV1) is at least 30% of the expected normal value

You likely don't qualify if…

you are a current tobacco smoker
your bronchiectasis is caused by cystic fibrosis, immune deficiency, or other specific genetic conditions
you have active mycobacterial lung infection or have not completed treatment for it
you have a history of severe coughing up blood that required medical intervention or blood transfusion
you have an active autoimmune disease or are taking immunosuppressive medications

What participation looks like

If you are selected, you will be randomly assigned to receive either the new medication or placebo for 24 weeks. You will take your assigned treatment regularly and visit the clinic for check-ups, where doctors will monitor your mucus production, lung function, and overall health. The study will track how well the medication works and watch for any side effects.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(1 site)

United States

Advanced Pulmonary Research Institute- Site Number : 8400001, Loxahatchee Groves, Florida